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a b s t r a c t
We report the fatty acid composition of mother's own human milk from one of the largest US cohorts of
lactating mothers of preterm infants. Milk fatty acid data were used as a proxy for intake at enrollment in
infants (n¼150) who received human milk with a powder human milk fortiﬁer (HMF; Control) or liquid
HMF [LHMF; provided additional 12 mg docosahexaenoic acid (DHA), 20 mg arachidonic acid (ARA)/
100 mL human milk]. Mothers provided milk samples (n¼129) and reported maternal DHA consump-
tion (n¼128). Infant blood samples were drawn at study completion (Study Day 28). Human milk and
infant PPL fatty acids were analyzed using capillary column gas chromatography.
DHA and ARA were within ranges previously published for US term and preterm human milk.
Compared to Control HMF (providing no DHA or ARA), human milk fortiﬁed with LHMF signiﬁcantly
increased infant PPL DHA and ARA and improved preterm infant DHA and ARA status.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Human milk is considered the preferred source of infant
nutrition. The European Society of Paediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) recommends the addition of
supplemental nutrients to human milk to meet preterm infant
requirements [1]. Supplementation of human milk with human
milk fortiﬁer (HMF) provides calories as well as macro- and micro-
nutrients at levels approximating estimated preterm infant needs
[2]. Infants born prematurely have low total body long chain
polyunsaturated fatty acid (LCPUFA) stores [3,4] and the docosa-
hexaenoic acid (DHA) and arachidonic acid (ARA) content of
preterm human milk may be insufﬁcient to meet increased needs.
Therefore the current ESPGHAN standard for preterm infants also
recommends fortiﬁcation of mother's own human milk as neces-
sary to meet high LCPUFA requirements (11–27 mg DHA/100 kcal
and 16–39 mg ARA/100 kcal) or use of infant formulas designed
for premature infants [1]. Preterm infant DHA and ARA status
rapidly declines [5,6] and low whole blood DHA and/or ARA are
associated with poor clinical outcomes, such as increased risk of
chronic lung disease and late-onset sepsis [6]. Consequently,
postnatal delivery of dietary LCPUFAs in the recommended range
represents a challenge for those caring for infants receiving human
milk or formula.
Preterm formulas have been developed based on worldwide
human milk DHA and ARA data in order to provide standardized
fortiﬁcation [7]. Human milk long chain n-3 and n-6 fatty acids can
vary at both population and individual levels and depend parti-
cularly on maternal dietary pattern and habits [7–12]. For exam-
ple, analysis of dietary fatty acid intake and plasma n-3 and n-6
fatty acids from pregnant Canadian women demonstrated that
dietary DHA intakes in some women during the third trimester
were below that necessary for DHA accretion in both fetal and
maternal tissues [13]. Western diets with low intake of n-3-rich
ﬁsh are also reﬂected in lower maternal blood DHA [7,9]. Human
milk ARA concentrations are typically higher, but less variable,
than DHA [7]. Consequently, clinical trials of preterm formulas
providing 17 mg DHA and 34 mg ARA per 100 kcal as fed (approxi-
mately 0.33% and 0.66% of total fatty acids, respectively,
for formulas with 5.1 g total fat/100 kcal formula) have demon-
strated improved growth and development compared with similar
formulas with no LCPUFAs [14,15].
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Given the increased likelihood for suboptimal DHA and ARA
status and risk for the associated negative consequences in
premature infants, DHA and ARA in a commercially sterile liquid
HMF (LHMF; Enfamils Mead Johnson Nutrition, Evansville, IN)
were targeted, when added to “typical” US human milk, to be
similar to the levels studied in preterm formulas. Appropriate
absorption of preformed DHA and ARA added in preterm infant
formula, as measured by metabolic balance studies [16] and from
fortiﬁed human milk, as measured by increases in blood levels [17]
has been previously demonstrated with no evidence that fortifying
human milk with these fatty acids negatively affects availability
from human milk. We recently demonstrated that fortiﬁcation
with LHMF, formulated to increase the DHA, ARA, total fat, and
protein content of human milk, signiﬁcantly improved preterm
infant growth when compared to milk fortiﬁed using a powder
HMF without DHA or ARA (Control, Mead Johnson Nutrition) [18].
As part of that study, we collected mother's own preterm milk to
provide baseline information on unfortiﬁed milk and infant
plasma samples to examine how dietary provision of a standar-
dized level of DHA and ARA affects preterm infant status. Here we
report on the fatty acid composition of preterm human milk from
this large US cohort of lactating mothers, as well as LCPUFAs in
plasma phospholipids of their infants.
2. Methods
Participants in this study (150 premature infants and their
mothers) were recruited for a double-blind, randomized, con-
trolled, prospective study to evaluate growth, tolerance and safety
of a new ultra-concentrated LHMF [18]. Brieﬂy, at enrollment the
infants were r30 3/7 weeks gestational age with birth weights
r1250 g, exclusively fed unfortiﬁed human milk (mother's own or
donor milk) with enteral intake of Z80 mL/kg per day, and had no
congenital malformations or underlying disease likely to interfere
with growth or tolerance of fortiﬁed milk. For 28 days, or until
hospital discharge or discontinuation of breast milk feedings,
infants received human milk (mother's own or donor milk)
supplemented with either a powder HMF (Control) or the LHMF
beginning at half strength on Study Day 1 and full strength
thereafter. The study was conducted at 14 sites from 7 states
(Florida, Nebraska, North Carolina, Illinois, Arkansas, New York,
and Virginia). A parent or guardian of each infant provided written
informed consent. Institutional review boards at each study site
reviewed and approved the study protocol. Medically-conﬁrmed
serious adverse events were monitored and documented through-
out the study. At study enrollment, data on infant birth character-
istics were collected [18]. In addition, mothers were asked if they
regularly (Z1 time per week) consumed any ﬁsh and/or DHA
supplements during the last 12 weeks of pregnancy. Responses
were recorded as “yes” or “no.”
2.1. Study fortiﬁers
Preterm human milk fortiﬁed with LHMF provides 20% more
protein and almost double the amount of DHA and ARA when
compared with preterm milk fortiﬁed with Control HMF. The
ranges for DHA and ARA levels naturally observed in human milk
support the nutritional acceptability and safety of ranges for the
calculated levels of DHA and ARA the LHMF was formulated to
provide as well as their estimated ratio in human milk fortiﬁed
with LHMF. For example, adding LHMF to milk corresponding to
the lowest mean US values (0.15% DHA and 0.4% ARA[7]) would
increase levels in fortiﬁed milk to approximately 0.29% DHA and
0.57% ARA (or 18 mg DHA and 35 mg ARA per 100 kcal; assuming
total fat of 3.5 g/100 mL in unfortiﬁed preterm human milk and
6.1 g/100 kcal in milk fortiﬁed with LHMF). Addition of LHMF to
human milk with as much as 1% DHA and/or ARA would lower the
level of the LCPUFAs as a percent of total fat (to 0.8% DHA and
0.94% ARA) in fortiﬁed human milk. Using the reported values for
worldwide means for DHA and ARA, Table 1 shows the calculated
macronutrient and polyunsaturated fatty acid (PUFA) estimates for
content of preterm milk fortiﬁed with study fortiﬁers at full
strength.
2.2. Fatty acid analysis
A single milk sample (1–2 ml) was collected from each mother
no earlier than postpartum day 6. The samples were collected after
the “let down” reﬂex occurred or following a complete expression
of milk to ensure a homogeneous sample. On Study Day 28, blood
samples (1 ml) were obtained from the infants and plasma
separated from RBCs by centrifugation. Milk and infant plasma
samples were frozen at 20 1C and shipped on dry ice to the
Retina Foundation of the Southwest (Dallas, TX) for fatty acid
analysis. Lipids were extracted, total phospholipids isolated, and
fatty acid methyl esters analyzed by capillary column gas chro-
matography as previously described [19]. Fatty acids in milk and
infant plasma phospholipids (PPLs) were expressed as weight
percent of total fatty acids. No donor milk was analyzed.
2.3. Sample size determination and statistical methods
A sample size of 50 infants per study group was originally
determined adequate to detect group differences in growth [18].
Fisher's exact test was used to analyze maternal consumption of
ﬁsh and/or use of DHA supplements during the last 12 weeks of
pregnancy. The Kruskal–Wallis test was used to analyze the fatty
acid content of breast milk and infant plasma phospholipids.
Infant plasma fatty acid analyses were conducted for two data
sets. A primary analysis included data from all infants who had a
blood sample drawn no more than 3 days after the last feeding of
human milk fortiﬁed with study HMF. A secondary analysis was
based on a subset of infants included in the primary analysis who
met the following additional criteria (per-protocol efﬁcacy analy-
sis): received Z80% of their energy intake from fortiﬁed human
milk for at least the ﬁrst two weeks of the study and were NPO (nil
per os) for no more than 2 days during this period, consumed
study fortiﬁer at full strength on Study Day 3, received no
glucocorticoid therapy during the full 28 day study, and had no
disease or illness that affected growth.
Table 1
Estimated macronutrients and PUFA in fortiﬁed human milk.
Nutrient 4 Packets powder
HMF (Control)þ100 mL
human milk (per 100 kcal)
4 Vials liquid HMF
(LHMF)þ100 mL
human milk (per 100 kcal)
Protein (g) 3.4 4
Fat (g) 5.6 6.1
Linoleic acid (mg) 730 730
α-Linolenic acid (mg) 54 54
ARA (mg) 20a 38
DHA (mg) 13.8a 24
Carbohydrate (g) 9.3 7.7
a None added; contribution from human milk only. Powder HMF does not
include DHA or ARA; Human milk levels calculated using published mean values of
0.32% of total fatty acids for DHA and 0.47% of total fatty acids for ARA [7]. LHMF
provides 12 mg DHA and 20 mg ARA when added to 100 ml (66 kcal) human milk.
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3. Results
3.1. Study population
As previously reported, between October 2008 and July 2010,
150 premature infants were enrolled and randomized [18]. Brieﬂy,
a total of 146 enrolled infants consumed some study fortiﬁer
(LHMF: 74; Control: 72) and 106 infants completed the full 28 day
study (LHMF: 51, 65%; Control: 55, 76%). Infant birth characteristics
including anthropometrics (weight, length, head circumference),
gestational age, gender, APGAR score, race, ethnicity, delivery type
(vaginal vs cesarean section) and birth type (singleton or twin) as
well as study completion rates did not differ between groups [18].
The use of donor milk occurred at two study sites. There were no
group differences in the percentage of infants who consumed
donor milk (LHMF: 14, 19%; Control: 18, 25%; P¼0.427).
3.2. Human milk fatty acid composition
Of the 150 initially enrolled, 129 mothers (64 with infants in the
LHMF and 65 in the Control group) provided a single, unfortiﬁed
human milk sample for fatty acid analysis (Fig. 1). The median
lactational age was 19 days postpartum (min: 6, IQR: 13–28, max:
50; mean7SD: 20.9710.4 days). Fatty acid (mean7SD and median
values, as a percentage of total fatty acids) composition of preterm
human milk is provided in Table 2. When analyzed by infant study
group (LHMF vs Control) few signiﬁcant differences were detected for
measured human milk fatty acids (data not shown); exceptions
(median, IQR) were 16:0 (LHMF: 21.08%, 19.50–22.16% vs Control:
20.39%, 18.32–21.65%; P¼0.024) and 22:1 (LHMF: 0.10%, 0.08–0.13%
vs Control: 0.08%, 0.07–0.10%; P¼0.009).
3.3. Infant PPL fatty acids at Study Day 28
Infant PPL saturated, monounsaturated, and PUFA are reported
by primary (all infants who provided a blood sample: LHMF, 46;
Control, 49) and secondary analysis (per-protocol efﬁcacy data set:
LHMF, 22; Control, 28) in Table 3. Saturated fatty acids (mean7
standard error) were not signiﬁcantly different between study
groups, with the exception of signiﬁcantly lower 16:0 (by primary
analysis) for the LHMF compared to the Control group. With the
exception of signiﬁcantly lower 18:1 levels (by primary and
secondary analysis) and 16:1 levels (by primary analysis only)
for the LHMF compared to the Control group, no other group
Human milk samples provided by mothers 
of enrolled participants, n=129
Primary PPL data set
(Control, 49; LHMF, 46)
Blood samples from infants who 
completed study through Day 28, n=95
Secondary PPL data set
(Control, 28; LHMF, 22)
DHA−, n=76
(Control, 40; LHMF, 36)
DHA+, n=52
(Control, 25; LHMF, 27)
Human milk data set
(Control, 65; LHMF, 64)
Milk FA analysis Infant PPL FA analysis
Human milk data set distributed by 
maternal DHA consumption
Fig. 1. Study ﬂow of (A) human milk samples provided by mother of enrolled participants for fatty acid (FA) analysis (n¼129) and clustering of data by maternal DHA
consumption: no consumption of DHA supplements or ﬁsh (DHA) vs regular (≥1 time per week) maternal consumption of DHA supplements or ﬁsh (DHAþ) and (B) blood
samples from participants who completed the study through Day 28 (n¼95) with data sets deﬁned as primary (all samples) and secondary (per-protocol efﬁcacy analysis)
for Control and LHMF study groups.
Table 2
Preterm human milk fatty acids as a percentage of total fatty acids (n¼129).a
Fatty acid Mean SD Median Min. IQR Max.
Saturated 48.42 5.67 48.17 35.77 44.69–52.18 63.48
6:0 (Caproic) 0.07 0.02 0.06 0.01 0.05–0.08 0.12
8:0 (Caprylic) 0.26 0.08 0.26 0.04 0.20–0.31 0.46
10:0 (Capric) 2.16 0.52 2.11 0.94 1.81–2.54 3.48
12:0 (Lauric) 9.54 2.95 9.33 2.65 7.51–11.34 17.84
14:0 (Myristic) 9.24 2.95 8.94 3.47 7.41–10.60 18.49
15:0 0.26 0.08 0.23 0.09 0.20–0.30 0.51
16:0 (Palmitic) 20.73 2.42 20.62 15.24 18.90–22.05 29.16
17:0 0.27 0.05 0.27 0.14 0.23–0.31 0.49
18:0 (Stearic) 5.61 0.96 5.47 3.50 5.01–6.22 8.82
20:0 (Arachidic) 0.15 0.03 0.15 0.08 0.13–0.17 0.25
22:0 (Behenic) 0.07 0.02 0.07 0.03 0.05–0.08 0.16
24:0 0.07 0.02 0.07 0.02 0.06–0.09 0.15
Monounsaturated 30.78 4.28 30.90 19.12 28.13–33.11 42.67
14:1 0.20 0.07 0.19 0.07 0.14–0.23 0.40
16:1 2.13 0.72 2.09 0.82 1.57–2.55 4.77
18:1 27.93 3.89 28.05 17.44 25.44–30.10 37.96
20:1 0.37 0.07 0.36 0.23 0.32–0.41 0.54
22:1 0.10 0.04 0.09 0.05 0.07–0.11 0.26
24:1 0.06 0.03 0.05 0.02 0.04–0.07 0.16
n-3 PUFA 1.81 0.48 1.82 0.71 1.46–2.10 3.07
18:3n-3 (ALA) 1.26 0.38 1.26 0.45 1.01–1.45 2.48
18:4n-3 0.02 0.02 0.02 0.00 0.01–0.03 0.07
20:3n-3 0.07 0.03 0.07 0.02 0.06–0.09 0.16
20:5n-3 (EPA) 0.05 0.04 0.04 0.00 0.03–0.06 0.27
22:5n-3 (DPAn-3) 0.13 0.05 0.12 0.06 0.10–0.15 0.34
22:6n-3 (DHA) 0.28 0.17 0.23 0.06 0.18–0.31 1.06
n-6 PUFA 18.98 3.40 18.72 11.03 17.18–20.94 29.32
18:2n-6 (LA) 16.95 3.29 16.75 9.21 15.13–18.95 27.38
18:3n-6 0.10 0.06 0.09 0.02 0.06–0.13 0.36
20:2n-6 0.48 0.14 0.45 0.23 0.39–0.56 0.87
20:3n-6 (DGLA) 0.55 0.15 0.52 0.31 0.43–0.63 1.18
20:4n-6 (ARA) 0.61 0.14 0.61 0.32 0.53–0.69 1.22
22:2n-6 0.07 0.04 0.06 0.02 0.05–0.09 0.27
22:4n-6 0.15 0.05 0.15 0.06 0.11–0.18 0.35
22:5n-6 (DPAn-6) 0.06 0.03 0.06 0.01 0.04–0.08 0.19
a Unfortiﬁed mother's own preterm milks were collected at (mean7SD)
20.9710.4 days postpartum.
C.L. Berseth et al. / Prostaglandins, Leukotrienes and Essential Fatty Acids 91 (2014) 97–103 99
Table 3
Primary and secondary analysis of preterm infant PPL fatty acids (as a percentage of total fatty acids) at Study Day 28.
Fatty acid Study group Primary P Secondary P
n Mean SE n Mean SE
Saturated Control 49 44.19 0.28 0.835 28 44.13 0.21 0.891
LHMF 46 43.95 0.46 22 44.04 0.82
14:0 Control 49 0.37 0.02 0.639 28 0.38 0.02 0.696
LHMF 46 0.39 0.03 22 0.39 0.03
15:0 Control 49 0.10 0.00 0.461 28 0.10 0.00 0.558
LHMF 46 0.10 0.00 22 0.10 0.00
16:0 Control 49 24.57 0.27 0.036a 28 24.59 0.32 0.137
LHMF 46 23.74 0.29 22 23.97 0.45
17:0 Control 49 0.35 0.01 0.297 28 0.35 0.01 0.123
LHMF 46 0.36 0.01 22 0.37 0.01
18:0 Control 49 16.99 0.19 0.070 28 16.91 0.27 0.265
LHMF 46 17.55 0.25 22 17.41 0.42
20:0 Control 49 0.53 0.02 0.789 28 0.53 0.03 0.922
LHMF 46 0.53 0.02 22 0.52 0.03
22:0 Control 49 0.71 0.04 0.988 28 0.68 0.05 0.830
LHMF 46 0.70 0.04 22 0.70 0.06
24:0 Control 49 0.58 0.03 0.817 28 0.59 0.04 0.830
LHMF 46 0.58 0.04 22 0.58 0.05
Monounsaturated Control 49 11.18 0.17 0.019a 28 11.09 0.16 0.006a
LHMF 46 10.63 0.22 22 10.18 0.25
14:1 Control 49 0.02 0.00 0.537 28 0.03 0.00 0.938
LHMF 46 0.03 0.00 22 0.02 0.00
16:1 Control 49 0.47 0.03 0.048a 28 0.47 0.03 0.132
LHMF 46 0.39 0.02 22 0.39 0.03
18:1 Control 49 8.60 0.16 0.044a 28 8.51 0.16 0.015a
LHMF 46 8.25 0.22 22 7.92 0.21
20:1 Control 49 0.24 0.01 0.864 28 0.25 0.01 0.274
LHMF 46 0.24 0.01 22 0.23 0.01
22:1 Control 49 0.16 0.01 0.376 28 0.17 0.02 0.725
LHMF 46 0.17 0.01 22 0.16 0.01
24:1 Control 49 1.69 0.08 0.242 28 1.68 0.09 0.265
LHMF 46 1.54 0.07 22 1.46 0.10
n-3 PUFA Control 49 4.21 0.10 0.041a 28 4.26 0.13 0.033a
LHMF 46 4.54 0.13 22 4.81 0.21
18:3n-3(ALA) Control 49 0.17 0.01 0.582 28 0.15 0.01 0.558
LHMF 46 0.16 0.01 22 0.15 0.01
18:4n-3 Control 49 0.01 0.00 0.410 28 0.01 0.00 0.807
LHMF 46 0.02 0.00 22 0.02 0.00
20:3n-3 Control 49 0.06 0.00 0.050 28 0.06 0.00 0.097
LHMF 46 0.06 0.00 22 0.05 0.00
20:5n-3 (EPA) Control 49 0.37 0.02 0.846 28 0.34 0.02 0.257
LHMF 46 0.40 0.04 22 0.44 0.07
22:5n-3 (DPAn-3) Control 49 0.50 0.01 0.001a 28 0.50 0.01 0.005a
LHMF 46 0.43 0.02 22 0.43 0.02
22:6n-3 (DHA) Control 49 3.09 0.09 0.003a 28 3.18 0.12 0.005a
LHMF 46 3.48 0.10 22 3.72 0.16
n-6 PUFA Control 49 40.34 0.31 0.682 28 40.44 0.30 0.984
LHMF 46 40.82 0.45 22 40.90 0.79
18:2n-6 (LA) Control 49 22.87 0.35 0.044a 28 22.80 0.35 0.012a
LHMF 46 22.13 0.46 22 21.36 0.65
18:3n-6 Control 49 0.08 0.00 0.388 28 0.08 0.01 0.282
LHMF 46 0.09 0.01 22 0.10 0.01
20:2n-6 Control 49 0.58 0.02 0.136 28 0.59 0.02 0.037a
LHMF 46 0.53 0.02 22 0.51 0.02
20:3n-6 (DGLA) Control 49 2.92 0.09 0.011a 28 3.03 0.12 0.005a
LHMF 46 2.61 0.09 22 2.54 0.12
20:4n-6 (ARA) Control 49 12.72 0.26 0.001a 28 12.93 0.29 o0.001a
LHMF 46 14.28 0.33 22 15.08 0.44
22:2n-6 Control 49 0.08 0.01 0.311 28 0.07 0.01 0.953
LHMF 46 0.07 0.01 22 0.07 0.01
22:4n-6 Control 49 0.39 0.02 0.522 28 0.39 0.02 0.338
LHMF 46 0.37 0.01 22 0.36 0.02
22:5n-6(DPAn-6) Control 49 0.71 0.12 0.766 28 0.55 0.09 0.506
LHMF 46 0.74 0.13 22 0.89 0.23
n-9 PUFA
20:3n-9 Control 49 0.08 0.01 0.344 28 0.08 0.02 0.233
LHMF 46 0.07 0.01 22 0.07 0.01
a Statistically signiﬁcant differences between Control and LHMF groups (Po0.05).
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differences in monounsaturated fatty acids were detected. Within
the n-3 PUFA measured, docosapentaenoic acid (DPAn-3; 22:5n-3)
was signiﬁcantly lower for the LHMF compared to the Control
group (by primary and secondary analysis) and DHA was signiﬁ-
cantly higher for the LHMF compared to the Control group (by
primary and secondary analysis). No signiﬁcant differences in
other n-3 PUFAs, including ALA and eicosapentaenoic acid (EPA;
20:5n-3), were detected. Within the n-6 PUFA measured, 20:2n-6
(by secondary analysis only), LA and dihomo-γ-linolenic acid
(DGLA; 20:3n-6) (by primary and secondary analysis) were sig-
niﬁcantly lower for the LHMF compared to the Control group, and
ARA was signiﬁcantly higher for the LHMF compared to the
Control group (by primary and secondary analysis).
3.4. Maternal consumption of DHA and infant PPL DHA status at
Study Day 28
Of the 129 mothers who provided human milk samples for
fatty acid analysis, 128 reported on maternal DHA consumption:
76 (59.4%) reported consuming no ﬁsh or DHA supplements
(DHA; Fig. 1) during the last 12 weeks of pregnancy, whereas
52 (40.6%) reported consuming DHA (DHAþ; further categorized
by supplements only: 25, 19.5%; ﬁsh only: 16, 12.5%; or both
supplements and ﬁsh: 11, 8.6%). When analyzed by infant study
group, there was no statistical difference between numbers of
mothers by DHA (LHMF: 36, 57.1%; Control: 40, 61.5%) or DHAþ
(LHMF: 27, 42.9%; Control: 25, 38.5%) group. However, mean
(7SD) human milk DHA (as a percentage of total fatty acids)
was 48% higher among mothers in the DHAþ (0.3470.21%) than
the DHA– group (0.2370.12%).
These data prompted our exploratory examination of how the
effects of maternal consumption of ﬁsh and/or DHA supplements
interfaced with infant DHA status at Study Day 28 among infants
who adhered most closely to the study protocol (Fig. 2). Using
maternal DHA consumption data that corresponded to infants
within the PPL DHA secondary analysis (per-protocol efﬁcacy), PPL
DHA content was highest for infants in the LHMF group whose
mothers reported regular consumption of DHA supplements and/
or ﬁsh (LHMF/DHAþ: 3.8270.89%). Infant PPL DHA content was
lowest for infants in the Control group whose mothers reported no
regular (o1 time per week) consumption of DHA supplements or
ﬁsh (Control/DHA: 3.0570.42%). The study was not powered to
provide statistical analysis for these post-hoc sub-groups. How-
ever, we wanted to provide this preliminary information as a
starting point for subsequent examination of the real-world
intersection of maternal DHA supplementation and infant LCPUFA
intake.
4. Discussion
This study surveyed the fatty acid composition of human milk
from one of the largest cohorts of lactating mothers of preterm
infants in the US to date, with samples representing 14 study
centers in 7 states. As expected, there were no signiﬁcant group
differences between LHMF and Control study participants'
mothers in unfortiﬁed, expressed human milk fatty acids, includ-
ing DHA and ARA, except for small differences noted in 16:0 and
22:1. DHA as a percentage of total fatty acids (median values) was
0.25% (IQR, 0.19–0.31%) for the LHMF and 0.23% (0.17–0.31%) for
the Control group; ARA was 0.60% (0.50–0.68%) for the LHMF and
0.62% (0.54–0.70%) for the Control group. Results from this study
are near the upper mean levels of DHA and ARA reported for US
term human milk [7] and consistent with levels analyzed in
a systematic review of reported preterm milk values [20]. Mother's
own preterm milk fatty acid data were used as a proxy for infant
intake at enrollment to assess the adequacy of standardized DHA
and ARA fortiﬁcation provided in a commercially sterile liquid
HMF. In the current analysis, we demonstrated PPL DHA and ARA
were signiﬁcantly higher in infants who received human milk
fortiﬁed with LHMF (providing an additional 12 mg DHA and
20 mg ARA per 100 mL human milk) when compared to the
powder Control HMF that provided no DHA or ARA. Consequently,
when provided in human milk, particularly milk low in LCPUFAs,
the improved liquid HMF enriched with DHA and ARA helps meet
the ESPGHAN recommendation for DHA and ARA fortiﬁcation.
Given the relatively short dietary intervention in our study,
measurement of LCPUFAs in plasma PL, rather than red blood cell
PL, was more likely to demonstrate signiﬁcant changes due to
dietary LCPUFAs, as noted previously [21]. On Study Day 28, PPL
DHA and ARA levels were signiﬁcantly higher for infants in the
LHMF compared to the Control group (primary and secondary
analysis). Infant PPL DHA and ARA in the current study were also
comparable to those recently reported for preterm infants who
received DHA provided via maternal supplementation, human
milk, or in infant formulas. For example, plasma DHA as percent
of total fatty acids increased signiﬁcantly (P¼0.009) by 2-fold
after 7 weeks of intervention in preterm Canadian infants whose
mothers received dietary DHA supplementation beginning within
the ﬁrst week postpartum compared to unsupplemented mothers
[22]. Preterm Australian infants received human milk (from their
mothers who had been supplemented with DHA or placebo for
resultant mean milk levels of 0.85% or 0.25% DHA) and/or formula
with 1.0% (High) or 0.33% (Standard) DHA from at least day 4 of life
until the expected date of delivery (median duration of feeding,
9.4 weeks) [23]. Reported means (7SD) for PPL DHA were
5.3270.94% (High) and 3.8970.67% (Standard) and for PPL ARA
were 10.2571.19% (High) and 11.1671.50% (Standard) by the end
of feeding [24]. German preterm infants enrolled within the ﬁrst
14 days of life received either human milk or one of three formulas
with ARA at 0.1% and DHA at 0.04% (low), 0.33% (medium), or
0.52% (high) over a 28 day period [21]. Increases in PPL DHA at day
28 were dose-dependent in formula-fed infants; medians reported
for PPL DHA were 3.46% in the human milk group and 2.15% (low),
3.41% (medium), and 4.20% (high) in formula groups.
In the current study, PPL LA was statistically higher in the
Control group (primary and secondary analysis) but differences
were small and not considered clinically signiﬁcant. Medians (21
to 23%) were similar to those reported for LA in Australian infants
for the High (21.72%) and Standard (20.51%) DHA groups. Higher
dietary LA intake is normally reﬂected in higher plasma and red
Fig. 2. Infant PPL DHA status on Study Day 28 (secondary analysis) for infants in
the LHMF (white bars) and Control groups (gray bars) as clustered by no
consumption (DHA) vs regular (≥1 time per week) maternal consumption of
DHA supplements or ﬁsh (DHAþ).
C.L. Berseth et al. / Prostaglandins, Leukotrienes and Essential Fatty Acids 91 (2014) 97–103 101
blood cell levels. In mothers from the current study, median values
for human milk LA as a percentage of total fatty acids were slightly
higher (16.75%) than those reported previously for US human milk
(14.78%) [12]; therefore, higher infant levels of PPL LA would be
expected. Infant PPL DPAn-3 and DGLA were also statistically
lower in the LHMF versus Control group (primary and secondary
analysis), although all values were consistent with aforementioned
levels reported for preterm German infants.[21] That study eval-
uated the effect of increasing DHA content of formulas (0.04% to
0.33% to 0.52%) on LCPUFA synthesis using stable-isotope labeled
LA and ALA, and found that increasing DHA did not inhibit ARA or
DHA synthesis. A signiﬁcant reduction in DPAn-3 production
associated with increased PPL DHA was also reported, in line with
our results demonstrating lower DPAn-3 in the LHMF group.
Similarly, an earlier study in adults reported a reduction of DGLA
synthesis with dietary ARA of 1.7 vs 0.21 g/day [25].
Our study also allowed examination of liquid HMF use within a
real-world neonatal ICU population in which approximately 75% of
study participants received fortiﬁed mother's own preterm human
milk. Because of the known beneﬁts of feeding human milk, donor
milk is offered with increased frequency in the NICU as a viable
alternative to mother's own milk [26]. However, the DHA content
of pooled US donor milk is typically lower when compared to
mother's own milk or formula and may not meet guidelines for
recommended provision of LCPUFAs to infants [3,27]. For example,
ARA levels ranged from 0.40% to 0.46% and DHA levels ranged
from 0.073% to 0.20% in pooled samples from milk banks in Texas,
North Carolina, California, and Iowa [28] and the DHA level from
one Ohio milk bank was reported at 0.1% [29]. In addition,
systematic review of fatty acid composition of human milk from
mothers of term versus preterm infants indicated higher DHA
levels in the latter, suggesting a signiﬁcant beneﬁt in feeding milk
of a matched lactational age to premature infants [20]. The current
data support the ESPGHAN-recommended use of mother's own
milk of matched lactational age and fortiﬁcation with the liquid
HMF to approximate the DHA and ARA levels appropriate for a
term infant.
It is well-established that maternal dietary DHA supplementa-
tion raises human milk DHA levels. This was evaluated in the
current study using self-reported consumption of ﬁsh and/or DHA
supplements (Z1 time per week during the last 12 weeks of
pregnancy), providing a rough estimate of maternal DHA intake.
This simple indicator demonstrated higher mean DHA in human
milk among mothers with use of dietary DHA sources versus those
without. As noted, although the study was not powered to analyze
post-hoc descriptive sub-group data with statistical strength, PPL
DHA was highest for infants with mothers who routinely con-
sumed DHA from ﬁsh and/or supplements prenatally who were
also randomized to receive LHMF. Over half of mothers who
provided milk samples consumed no supplemental or signiﬁcant
dietary source of DHA late in gestation, suggesting poor compli-
ance with expert recommendations of at least 200 mg/day dietary
DHA [27]. The human milk data in the current study demonstrate
the continued need to explore and encourage increased maternal
DHA intake or supplementation in US women.
Overall, this study provided much-needed data on fatty acid
composition of preterm mother's own human milk from a large US
cohort of lactating mothers, representing an essential regional
cross-section. Given the importance of DHA and ARA for preterm
infant growth and development [14,15], and emerging evidence
that even higher levels of DHA may provide additional beneﬁts
[17,23], it is important to assure that preterm infants fed fortiﬁed
human milk also receive, at minimum, the levels of DHA and ARA
found in premature formulas. To this end, adding the improved,
commercially sterile liquid HMF to human milk signiﬁcantly
increased the preterm milk content of DHA and ARA to levels
within the expert-recommended range and improved the DHA
and ARA status of preterm infants. Results from our simple dietary
survey also demonstrate the need to improve US human milk DHA
status through increased maternal dietary supplementation at
expert-recommended levels.
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